Masaoka T, Motoyoshi K, Takaku F, Kato S, Harada M, Kodera Y, Kanamaru A, Moriyama Y, Ohno R, Ohira M
Center for Adult Disease, Osaka, Japan.
Bone Marrow Transplant. 1988 Mar;3(2):121-7.
A phase II study of the use of colony stimulating factor derived from human urine (CSF-HU) was performed after bone marrow transplantation (BMT). Steady and rapid recovery of leukocyte and granulocyte numbers was observed. In most patients who received CSF-HU from day 1, leukocyte numbers started to increase on day 6 and monocytes and granulocytes on day 11. Significant differences in the days to recovery of leukocytes over 1 x 10(9)/l and of granulocytes over 0.5 x 10(9)/l were observed in comparison with non-randomized control patients. In some patients in whom recovery of leukocytes was delayed, CSF also seemed to be effective in increasing leukocyte numbers from 8 days after the start of administration. There was no significant difference in the rate of relapse of leukemia between the two groups. CSF-HU seems very promising as a treatment of patients after BMT by shortening the period of leukopenia or granulocytopenia.
在骨髓移植(BMT)后开展了一项关于使用源自人尿的集落刺激因子(CSF-HU)的II期研究。观察到白细胞和粒细胞数量稳步且快速恢复。在大多数从第1天开始接受CSF-HU的患者中,白细胞数量在第6天开始增加,单核细胞和粒细胞在第11天开始增加。与非随机对照患者相比,白细胞恢复至超过1×10⁹/L以及粒细胞恢复至超过0.5×10⁹/L的天数存在显著差异。在一些白细胞恢复延迟的患者中,CSF似乎在给药开始8天后增加白细胞数量方面也有效。两组之间白血病复发率无显著差异。CSF-HU作为BMT后患者的一种治疗方法,通过缩短白细胞减少或粒细胞减少期似乎非常有前景。